%0 Journal Article
%T New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.
%A Tamargo J
%A Agewall S
%A Borghi C
%A Ceconi C
%A Cerbai E
%A Dan GA
%A Ferdinandy P
%A Grove EL
%A Rocca B
%A Magavern E
%A Sulzgruber P
%A Semb AG
%A Sossalla S
%A Niessner A
%A Kaski JC
%A Dobrev D
%J Eur Heart J Cardiovasc Pharmacother
%V 10
%N 3
%D 2024 May 4
%M 38379024
暂无%R 10.1093/ehjcvp/pvae013
%X Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.